Teplizumab - preventative approaches to type 1 diabetes mellitus

被引：0
作者：
Seewoodhary, Jason [1 ]
Silveira, Angela [2 ]
机构：
[1] NHS Northwest London, Brent Integrated Hlth Board, London, England
[2] Saskatchewan Hlth Author, Publ Hlth & Prevent Med, Saskatoon, SK, Canada
来源：
PRACTICAL DIABETES | 2023年 / 40卷 / 02期
关键词：
teplizumab; type 1 diabetes mellitus; immunotherapy; anti-CD3; screening; INSULIN; TRIAL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Immunotherapies offer the potential to reprogramme the immune system to halt autoimmune destruction of insulin-producing beta-cells within the pancreas, dealing with the root cause of type 1 diabetes (T1DM) for the first time. Leading on from this, teplizumab, the first drug in this class, has been found to delay the onset of T1DM by an average of three years in people stratified high risk for developing T1DM. This review will critically consider the evidence basis underlying the utility of teplizumab in the management of T1DM. Copyright (c) 2023 John Wiley & Sons.
引用
收藏
页码：35 / +
页数：5
相关论文
共 50 条
  • [1] Teplizumab: type 1 diabetes mellitus preventable?
    Misra, Saurav
    Shukla, Ajay Kumar
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (05) : 609 - 616
  • [2] Journey of Teplizumab: A Promising Drug in the Treatment of Type 1 Diabetes Mellitus
    Sharma, Nikita
    Das, Debashree Debasish
    Chawla, Pooja A.
    CURRENT DIABETES REVIEWS, 2025, 21 (01) : e250124226249
  • [3] Teplizumab: type 1 diabetes mellitus preventable?
    Saurav Misra
    Ajay Kumar Shukla
    European Journal of Clinical Pharmacology, 2023, 79 : 609 - 616
  • [4] Teplizumab for Treatment of Type I Diabetes Mellitus
    Skelley, Jessica W.
    Elmore, Lindsey K.
    Kyle, Jeffrey A.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (10) : 1405 - 1412
  • [5] Teplizumab therapy for type 1 diabetes
    Masharani, Umesh B.
    Becker, Joseph
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (03) : 459 - 465
  • [6] Safety and Efficacy of Teplizumab for Treatment of Type One Diabetes Mellitus: A Systematic Review and Meta-Analysis
    Nourelden, Anas Zakarya
    Elshanbary, Alaa Ahmed
    El-Sherif, Loalo'a
    Benmelouka, Amira Yasmine
    Rohim, Hagar Ismail
    Helmy, Sara Kamel
    Sayed, Merhan Kamal
    Ismail, Ammar
    Ali, Ahmed Said
    Ragab, Khaled Mohamed
    Zaazouee, Mohamed Sayed
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2021, 21 (10) : 1895 - 1904
  • [7] Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review
    Buddhavarapu, Venkata
    Dhillon, Gagandeep
    Grewal, Harpreet
    Sharma, Pranjal
    Kashyap, Rahul
    Surani, Salim
    WORLD JOURNAL OF DIABETES, 2024, 15 (08)
  • [8] Teplizumab Therapy to Delay the Onset of Type 1 Diabetes
    Novograd, Joel
    Frishman, William H.
    CARDIOLOGY IN REVIEW, 2024, 32 (06) : 572 - 576
  • [9] Teplizumab’s immunomodulatory effects on pancreatic β-cell function in type 1 diabetes mellitus
    Emmanuel Kokori
    Gbolahan Olatunji
    Ikponmwosa Jude Ogieuhi
    John Ehi Aboje
    Doyin Olatunji
    Sikiru Ademola Aremu
    Stephen Chukwuemeka Igwe
    Abdulrahmon Moradeyo
    Yusuf Ismaila Ajayi
    Nicholas Aderinto
    Clinical Diabetes and Endocrinology, 10 (1):
  • [10] Evaluation of teplizumab's efficacy and safety in treatment of type 1 diabetes mellitus: A systematic review and meta-analysis
    Ma, Xiao-Lan
    Ge, Dan
    Hu, Xue-Jian
    WORLD JOURNAL OF DIABETES, 2024, 15 (07)
12345